Thus, the NCCN recommends the use of only three classes of medical therapy: α-IFN, somatostatin receptor agonists and vascular endothelial growth factor (VEGF) inhibitors for the treatment of meningioma (130, 131). The gene discussed is VEGFA; the disease is meningioma.